Literature DB >> 30123926

Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant).

Claudia Mendoza-Pinto1,2, Mario García-Carrasco1,2, Ricard Cervera3.   

Abstract

PURPOSE OF REVIEW: The antiphospholipid syndrome (APS) is characterized by the development of thrombotic events and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). An infectious etiology for this syndrome has been postulated. The present review is aimed to summarize recent evidence about the role of infections and vaccines in the pathogenesis of the APS (including its catastrophic variant). RECENT
FINDINGS: There is an increased risk of developing aPL in various infections, particularly in viral infections. The most frequent infection related to aPL has been hepatitis C virus. These antibodies may be associated with thromboembolic events, including catastrophic APS. There is a link between vaccinations, such as the tetanus toxoid and aPL, due to molecular mimicry between the two molecules. Accumulated evidence supports that the presence of aPL is associated with a variety of infections, including viruses, bacteria, fungi, and parasites, and the main mechanism to explain this correlation is molecular mimicry. Moreover, a link between vaccinations, such as the tetanus toxoid, and APS has also been described.

Entities:  

Keywords:  Antiphospholipid syndrome; Infections; Thrombosis; Vaccines

Mesh:

Year:  2018        PMID: 30123926     DOI: 10.1007/s11926-018-0773-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  49 in total

1.  Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population.

Authors:  W Shi; S A Krilis; B H Chong; S Gordon; C N Chesterman
Journal:  Aust N Z J Med       Date:  1990-06

Review 2.  Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence.

Authors:  Gabriela Medina; Eduardo Briones-García; María Pilar Cruz-Domínguez; Oscar I Flórez-Durante; Luis J Jara
Journal:  Autoimmun Rev       Date:  2017-02-13       Impact factor: 9.754

Review 3.  'Primary', 'secondary' and other variants of the antiphospholipid syndrome.

Authors:  R A Asherson; R Cervera
Journal:  Lupus       Date:  1994-08       Impact factor: 2.911

Review 4.  Viral hepatitis and anti-phospholipid antibodies positivity: A systematic review and meta-analysis.

Authors:  Pasquale Ambrosino; Roberta Lupoli; Paolo Tarantino; Alessandro Di Minno; Luciano Tarantino; Matteo Nicola Dario Di Minno
Journal:  Dig Liver Dis       Date:  2015-03-17       Impact factor: 4.088

5.  Prevalence and disease associations of certain autoantibodies in elderly patients.

Authors:  A G Juby; P Davis
Journal:  Clin Invest Med       Date:  1998-02       Impact factor: 0.825

6.  Central serous chorioretinopathy and Helicobacter pylori.

Authors:  L Cotticelli; M Borrelli; A C D'Alessio; M Menzione; A Villani; G Piccolo; F Montella; M R Iovene; M Romano
Journal:  Eur J Ophthalmol       Date:  2006 Mar-Apr       Impact factor: 2.597

7.  Prevalence, significance, and specificity of antibodies to phospholipids in Q fever.

Authors:  J Ordi-Ros; A Selva-O'Callaghan; F Monegal-Ferran; Y Monasterio-Aspiri; C Juste-Sanchez; M Vilardell-Tarres
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

8.  Antibodies to anionic phospholipids and cofactors in kala-azar. Comparative study with malaria, toxoplasmosis and "autoimmune diseases".

Authors:  H Skouri; R Gandouz; I Kraiem; I Harrabi; M Ben Said
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

9.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

10.  Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers.

Authors:  Dirk Roggenbuck; Maria Orietta Borghi; Valentina Somma; Thomas Büttner; Peter Schierack; Katja Hanack; Claudia Grossi; Caterina Bodio; Paolo Macor; Philipp von Landenberg; Francesco Boccellato; Michael Mahler; Pier Luigi Meroni
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156

View more
  26 in total

Review 1.  Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis.

Authors:  Amelia Ruffatti; Antonia Calligaro; Carmelo S Lacognata; Anna D'Odorico; Anna Colpo; Fabrizio Cardin; Fiorella Calabrese
Journal:  Clin Rheumatol       Date:  2019-12-18       Impact factor: 2.980

Review 2.  Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy.

Authors:  Manuel Serrano; Gerard Espinosa; Antonio Serrano; Ricard Cervera
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

3.  Prevalence and coagulation correlation of anticardiolipin antibodies in patients with COVID-19.

Authors:  Hui Zeng; Meihong Cai; Han Xue; Wen Xie; Xinghua Long
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

4.  Should COVID-19 be branded to viral thrombotic fever?

Authors:  Rubens Carmo Costa-Filho; Hugo Caire Castro-Faria Neto; José Mengel; Marcelo Pelajo-Machado; Marco Aurélio Martins; Érica Távora Leite; Hugo Tannus Mendonça-Filho; Tatiana de Arruda Campos Brasil de Souza; Gonzalo Bentacor Bello; José Paulo Gagliardi Leite
Journal:  Mem Inst Oswaldo Cruz       Date:  2021-04-30       Impact factor: 2.743

Review 5.  Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review).

Authors:  Eugenio Cavalli; Alessia Bramanti; Rosella Ciurleo; Andrey I Tchorbanov; Antonio Giordano; Paolo Fagone; Cristina Belizna; Placido Bramanti; Yehuda Shoenfeld; Ferdinando Nicoletti
Journal:  Int J Mol Med       Date:  2020-06-25       Impact factor: 4.101

Review 6.  Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Authors:  Vanessa Bianconi; Francesco Violi; Francesca Fallarino; Pasquale Pignatelli; Amirhossein Sahebkar; Matteo Pirro
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

7.  Unusual case of antiphospholipid syndrome presenting as adrenal insufficiency.

Authors:  Sanval Ahmed Warriach; Mohamad Mustafa; Denis O'Keeffe; Michael Watts
Journal:  BMJ Case Rep       Date:  2020-03-17

Review 8.  Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?

Authors:  Rossella Talotta; Erle S Robertson
Journal:  Cytokine Growth Factor Rev       Date:  2021-05-28       Impact factor: 7.638

9.  Acute aortic thrombosis in COVID-19.

Authors:  Ciro Baeza; Alejandro González; Patricia Torres; Mateo Pizzamiglio; Ana Arribas; César Aparicio
Journal:  J Vasc Surg Cases Innov Tech       Date:  2020-07-17

Review 10.  The contact system in liver injury.

Authors:  Chandini Rangaswamy; Reiner K Mailer; Hanna Englert; Sandra Konrath; Thomas Renné
Journal:  Semin Immunopathol       Date:  2021-06-14       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.